BE-31405 is an antifungal antibiotic. BE-31405 can be isolated from the culture broth of the fungal strains such as Penicillium minioluteum F31405, Talaromyces siamensis FKA-61, and Phomopsis sp. FKA-62. BE-31405 exhibits potent growth inhibitory activity against pathogenic fungal strains including Candida albicans, Candida glabrata, and Cryptococcus neoformans. BE-31405 shows no cytotoxicity against mammalian cells.

(R)-MK-8353 ((R)-SCH900353) is the R-enantiomer of MK-8353). MK-8353 (SCH900353) is a potent, selective and orally active ERK1 and ERK2 inhibitor with IC50s of 23.0 nM and 8.8 nM, respectively.

S-3483, a Chlorogenic acid derivative, is a reversible, linear competitive glucose-6-phosphatase (Glc-6-Pase) system inhibitor. S-3483 inhibits Glc-6-Pase with a Ki 129 nM in rat liver microsomes. S-3483 specifically inhibits Glc-6-P transporter of renal and liver microsomes.

Carmaphycin-17 (CP-17) is a selective 20S proteasome inhibitor with an EC50 of 217  nM. Carmaphycin-17 has potent antimicrobial activity against Trichomonas vaginalis. Carmaphycin-17 overcomes Metronidazole resistance and significantly reduces parasite burden upon topical treatment without any apparent adverse effects in vaginal trichomonad infection mice model. Carmaphycin-17 can be used for sexually transmitted disease like trichomoniasis research.

(R)-Glutor is the R-enantiomer of Glutor. Glutor is a selective GLUT 1/2/3 inhibitor that can suppress glucose uptake. Glutor can inhibit glycolysis and has anti-tumor activity, inducing cell apoptosis.

MC-04124 is an efflux pump inhibitor. MC-04124 significantly enhances the activity of Levofloxacin against Pseudomonas aeruginosa.

Pro-Dasatinib (compound 2j), an amino acid analog of Dasatinib, is a potent Src/Abl kinase inhibitor. Pro-Dasatinib has antiproliferative activity against K652 leukemia cancer cells with an IC50 of 0.21 nM.

PSMA-MAL-5 is a PSMA ligand. PSMA-MAL-5 covalently binds to Cys466 of PSMA. PSMA-MAL-5 labeled with 177Lu and 225Ac has high radiostability and tumor uptake. PSMA-MAL-5 also effectively inhibits tumor growth. PSMA-MAL-5 can be used for SPECT/CT imaging and radionuclide therapy of prostate cancer.

VX-759 (VCH-759) is an orally active HCV NS5B RNA-dependent RNA polymerase inhibitor. VX-759 is promising for research of chronic hepatitis C.

Y2641, a etrahydro-β-carboline derivative, is an orally active dual RANKL/TNF-α inhibitor with Kd values of 3.984 μM and 18.59 μM for RANKL and TNF-α, respectively. Y2641 inhibits RANKL-induced osteoclastogenic and has anti-inflammatory and cartilage destruction. Y2641 can be used for study of osteoarthritis.

(+)-JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) that inhibits AR nuclear localization and transcriptional activity in the absence of androgen. (+)-JJ-450 is less active than (-)-JJ-450 in inhibiting prostate-specific antigen (PSA) expression in LN95 cells, possibly because (+)-JJ-450 targets the ligand binding domain (LBD) of AR. (+)-JJ-450 inhibits the transcriptional activity of AR and its splice variants (e.g., ARv7) by promoting the degradation of unliganded AR in the nucleus and reducing the binding of AR to androgen response elements (AREs). (+)-JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to enzalutamide (MDV3100).

ASP4000 hydrochloride is a potent, competitive, selective, orally active DPP4 inhibitor with an IC50 value of 2.25 nM against human recombinant DPP4. ASP4000 hydrochloride shows antihyperglycemic activity. ASP4000 hydrochloride can be used in the research of type 2 diabetes.

JTP 2942 is a thyrotropin-releasing hormone analogue. JTP 2942 can promote the release of Acetylcholine in the hippocampus and frontal cortex of rats. JTP 2942 possesses neuroprotective and cognitive-improving activities. JTP 2942 dose-dependently improves motor and neurological deficits in rat models of chronic focal cerebral ischemia. JTP 2942 can be used for the research of cerebral ischemia, motor neuron diseases, and other related conditions.

XV459 is an orally active platelet GPIIb/IIIa receptor antagonist. XV459 blocks all agonist induced platelet aggregation by binding to platelet GPIIb/IIIa receptors. XV459 can significantly prolong occlusion time, reduce thrombus weight, and maintain blood flow. XV459 can be used for anti thrombotic research.

BL-122 is a selective phosphodiesterase-5 (PDE-5) inhibitor. BL-122 can increase the level of cGMP in the tissue, promote the expression of nitric oxide (NO), and mediate the relaxation of smooth muscle. BL-122 can be used for the researches of inflammation, immunology and cardiovascular disease, such as asthma and hypertension.

MGS0008 is an orally active and brain-penetrant metabotropic glutamate receptor 2/3 (mGlu2/3) agonist. MGS0008 is promising for research of central nervous system disorders, including schizophrenia, anxiety, and neurodegenerative diseases.

SH6 is a transcription factor ZBTB7A degrader. SH6 is promising for research of β-hemoglobinopathies such as sickle cell disease (SCD) and β-thalassemia.

SMI-10B13 is an Oncostatin M (OSM) inhibitor with a KD of 6.6 μM. SMI-10B13 inhibits OSM-mediated STAT3 phosphorylation in T47D and MCF-7 cell lines (IC50 = 136 and 164 nM, respectively). SMI-10B13 shows anti-tumor effect in human breast cancer mice models.

AKT-100 is a p53 reactivation agent. AKT-100 significantly inhibits the proliferation of various ovarian and endometrial cancer cells at low concentrations. AKT-100 can upregulate cell cycle regulatory genes (such as p21, GADD45) and pro apoptotic genes (such as NOXA, DR5), and inhibit DNA repair pathways. AKT-100 is commonly used in cancer research.

(Rac)-VB-201 is the racemate of VB-201, an oxidized phospholipid small molecule that inhibits CD14- and toll-like receptor 2-dependent innate cell activation and suppresses atherosclerosis.

Cytaphat is a compound with hepatoprotective activity. Cytaphat has antioxidant, membrane-stabilizing and choleretic effects. Cytaphat can be used in the research of diseases such as acute toxic hepatopathy and liver injury.

Rp-dUTPαS (tetrasodium) is an isomer of the sulfur-containing nucleoride dUTP-α-S and an agonist of the purinergic P2Y2 receptor. Rp-dUTPαS (tetrasodium) selectively induces inositol phosphate accumulation in P2Y2-expressing 1321N1 cells with an EC50 of 12.5 μM.

NLCQ-1 (NSC 709257) is an orally active antibacterial agent targeting dormant Mycobacterium tuberculosis. NLCQ-1 is promising for research of tuberculosis.

IKE16 is a fungi-selective eukaryotic topoisomerase II inhibitor, with an IC50 value of 13.68 μM. IKE16 suppresses both the DNA relaxation activity and the decatenation activity of yTOPOII selectively. IKE16 shows moderate activity against standard fungal strains (Candida albicans ATCC 10231, Saccharomyces cerevisiae ATCC 89763) with a minimum inhibitory concentration (MIC) of 2 μg/mL against S. cerevisiae ATCC 89763. IKE16 exhibits high cytotoxicity against human cells, with an EC50 of 0.07 μM in HepG2 and 0.045 μM in HEK-293. IKE16 can be used for the study of antifungal infection.

HC2210 has an antibacterial effect against Mycobacterium abscessus (Mab) (EC50: 0.72 µM). HC2210 modulates the expression of Mab genes related to oxidative stress and lipid metabolism. HC2210 can be used in the study of Mab infection.

TNP-ATP is an antagonist of purinergic P2Y1, P2X3, and P2X2/3 receptors (IC50 = 6, 0.9, and 7 nM, respectively, in HEK293 cells expressing human receptors). TNP-ATP reduces acetate-induced calcium flux in 1321N1 cells expressing P2X3 and P2X2/3 receptors (IC50 = 100 and 62 nM, respectively). TNP-ATP dose-dependently attenuates acetate-induced abdominal contractions in a mouse visceral pain model (ED50 = 6.35 µmol/kg)[1][2].

Leucodelphinidin (Leukoefdin) is a flavonoid found in Terminalia plants with antiplasmodial activity against Plasmodium falciparum (3D7 and Dd2 strains). Leucodelphinidin exhibits cytotoxicity (CC50>250 μg/mL) toward Vero and Raw 264.7 cells. Leucodelphinidin is promising for research of antimalarial agents.

Ro-65-2299 is an orally active retiferol Vitamin D analogue and a potential VDR agonist (ED50 = 180 nM). Ro-65-2299 can induce thickening of the epidermis and exhibits antipsoriatic effect in hairless mice (ED50 = 7.5 mg/kg). Ro-65-2299 can be used for the researches of inflammation and immunology, such as psoriasis.

Rp-2'-Deoxyadenosine-5'-O-(1-thiodiphosphate) (Rp-dADP-α-S) sodium is an isomer of Sp-2'-Deoxyadenosine-5'-O-(1-thiodiphosphate) sodium.

Sp-2'-Deoxyadenosine-5'-O-(1-thiodiphosphate) (Sp-dADP-α-S) sodium is an isomer of Rp-2'-Deoxyadenosine-5'-O-(1-thiodiphosphate) sodium.